Advertisement
Advertisement
ELVN
Enliven Therapeutics, Inc. Common Stock
60.46
USDSponsored
+0.19
+0.32%
Aug 07, 15:59 UTC -4
Closed
After-Market
60.62
+0.16
+0.26%
ELVN Earnings Reports
Positive Surprise Ratio
ELVN beat 17 of 24 last estimates.
71%
Next Report
Date of Next Report
Aug 19, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.40
Implied change from Q1 26 (Revenue/ EPS)
--
/+5.26%
Implied change from Q2 25 (Revenue/ EPS)
--
/-18.37%
Enliven Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, ELVN reported earnings of -0.38 USD per share (EPS) for Q1 26, beating the estimate of -0.47 USD, resulting in a 19.49% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.14% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.40 USD, with revenue projected to reach -- USD, implying an increase of 5.26% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Guardian Pharmacy Services, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.28
Surprise
+3.76%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
FAQ
What were Enliven Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Enliven Therapeutics, Inc. Common Stock reported EPS of -$0.38, beating estimates by 19.49%, and revenue of $0.00, 0% as expectations.
How did the market react to Enliven Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 1.14%, changed from $40.29 before the earnings release to $40.75 the day after.
When is Enliven Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 19, 2026.
What are the forecasts for Enliven Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Enliven Therapeutics, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement